Five patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2038. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2038
Next term end
5
Patent families
When these terms end
Each bar runs from grant to computed term end. 2022 to 2043.202620302034203820422043
30 pending applications: term is not computable until grant.Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2039 · High confidence
Also notable
Ends Apr 2038 · High confidence
Also notable
Ends Nov 2042 · Medium confidence
Combinatorial Cancer Immunotherapy
US 11,419,898
The most cited patent in this portfolio, cited by 4 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2039.
Combinatorial Cancer Immunotherapy
US 11,446,332
The earliest of the three still in force, granted 2022 and renewed since. Its term ends first, in 2038.
Protein Payload Release
US 12,653,839
A family of 5 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2042.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 16, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Chimeric Receptors and Methods of Use Thereof (2023) | 1 in force | to May 2043 |
| Protein Payload Release | 1 in force | to Nov 2042 |
| Chimeric Receptors and Methods of Use Thereof (2021) | 1 in force | to May 2040 |
| Combinatorial Cancer Immunotherapy (2021) | 1 in force | to Oct 2039 |
| Combinatorial Cancer Immunotherapy (2019) | 1 in force | to Apr 2038 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,446,332 | Combinatorial Cancer Immunotherapy In force · High confidence | In force | High confidence | |
| US 11,419,898 | Combinatorial Cancer Immunotherapy In force · High confidence | In force | High confidence | |
| US 12,005,081 | Chimeric Receptors and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,653,839 | Protein Payload Release In force · Medium confidence | In force | Medium confidence | |
| US 12,611,458 | Chimeric Receptors and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 1 patent ended · 30 applications pending · 14 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.